Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Harmony Biosciences Holdings, Inc. - Common Stock (NQ:HRMY)

34.23 -1.05 (-2.98%)
Streaming Delayed Price Updated: 2:42 PM EST, Feb 19, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Harmony Biosciences Holdings, Inc. - Common Stock

< Previous 1 2 3 4 5 6 7 8 9 10 11 Next >
News headline image
Harmony Biosciences Holdings (NASDAQ:HRMY): A Prime GARP Investment with Strong Growth and a Reasonable Price ↗
Harmony Biosciences (HRMY) offers strong growth at a reasonable price. With high EPS growth, robust profitability, and a low P/E ratio, it's a top GARP stock. 
Via Chartmill
News headline image
Q3 2025 Earnings Season: A Market Navigating AI's Ascent Amidst Economic Shifts
The curtain has largely fallen on the Q3 2025 earnings season, revealing a financial landscape characterized by robust corporate performance, particularly in the technology and financial sectors,... 
Via MarketMinute
Topics Artificial Intelligence Economy Fraud
Harmony Biosciences Raises Full-Year Revenue Guidance Ahead Of Earnings: Why Are Wakix Franchise Numbers Crucial? ↗
Via Stocktwits
News headline image
Earnings Scheduled For August 5, 2025 ↗
 
Via Benzinga
News headline image
Harmony Biosciences Preannounces Strong Q3 2025 WAKIX Performance; Raises 2025 Revenue Guidance
From Harmony Biosciences Holdings, Inc.
Via Business Wire
News headline image
Harmony Biosciences Holdings (NASDAQ:HRMY) Presents a Compelling Undervalued Investment Case ↗
Harmony Biosciences (HRMY) is a value stock with a low P/E ratio, strong profitability, a healthy balance sheet, and solid growth potential. 
Via Chartmill
News headline image
Harmony Biosciences Holdings (NASDAQ:HRMY): A Growth Stock with a Promising Technical Setup ↗
Harmony Biosciences (HRMY) offers strong growth, high profitability, and an attractive valuation. Its positive technical setup suggests a potential breakout, making it a compelling stock to watch. 
Via Chartmill
News headline image
Top 3 Health Care Stocks That Are Preparing To Pump In Q4 ↗
 
Via Benzinga
News headline image
Harmony Biosciences Holdings (NASDAQ:HRMY) Presents an 'Affordable Growth' Opportunity ↗
Harmony Biosciences (HRMY) offers affordable growth with strong EPS & revenue expansion, a low P/E ratio, and robust profitability in rare neurological treatments. 
Via Chartmill
News headline image
Deep Dive Into Harmony Biosciences Hldgs Stock: Analyst Perspectives (6 Ratings) ↗
Analysts' ratings for Harmony Biosciences Hldgs (NASDAQ: HRMY) over the last quarter vary from bullish to bearish, as provided by 6 analysts. Summarizing their recent assessments, the table below... 
Via Benzinga
News headline image
Freeport-McMoRan, Harmony Biosciences, Cohu, And Other Big Stocks Moving Lower On Wednesday ↗
 
Via Benzinga
News headline image
Harmony Biosciences Stock Slumps After Rare Genetic Disorder Drug Fails Late-Stage Study ↗
The company said on Wednesday that its drug did not meet the primary endpoint of the trial primarily due to a higher-than-expected placebo response rate. 
Via Stocktwits
News headline image
Harmony Biosciences' Genetic Disorder Drug Disappoints In Phase 3 Study ↗
Harmony Biosciences' ZYN002 failed to meet its primary goal in a Fragile X Phase 3 trial, but the company points to pipeline growth. 
Via Benzinga
News headline image
12 Health Care Stocks Moving In Wednesday's Intraday Session ↗
 
Via Benzinga
News headline image
Harmony Biosciences Whiffs In 'Undruggable' Genetic Disease; Shares Tumble ↗
Shares plunged Wednesday as the inherited disease continued to be "undruggable" for the biotech company. 
Via Investor's Business Daily
News headline image
12 Health Care Stocks Moving In Wednesday's Pre-Market Session ↗
 
Via Benzinga
News headline image
Harmony Biosciences Provides Update From Its Phase 3 RECONNECT Study of ZYN002 in Fragile X Syndrome
From Harmony Biosciences Holdings, Inc.
Via Business Wire
News headline image
Harmony Biosciences Holdings (NASDAQ:HRMY) Presents a Compelling Value Investment Opportunity ↗
Harmony Biosciences (HRMY) is a value stock with strong fundamentals: low P/E, high profitability, robust financial health, and impressive growth prospects. 
Via Chartmill
News headline image
Harmony Biosciences Holdings (NASDAQ:HRMY) Emerges as a Top Affordable Growth Stock ↗
Harmony Biosciences (HRMY) exemplifies GARP investing with strong EPS growth, a low P/E ratio, and robust profitability in the rare neurology sector. 
Via Chartmill
News headline image
Harmony Biosciences to Present Rare Epilepsy Data at the 36th International Epilepsy Congress
From Harmony Biosciences Holdings, Inc.
Via Business Wire
News headline image
Harmony Biosciences Holdings (NASDAQ:HRMY) Presents a Compelling Value Investment Opportunity ↗
Harmony Biosciences (HRMY) is a value stock with strong fundamentals: undervalued P/E, high profitability, robust financial health, and impressive growth metrics. 
Via Chartmill
News headline image
Harmony Biosciences to Participate in 2025 Cantor Global Healthcare Conference
From Harmony Biosciences Holdings, Inc.
Via Business Wire
News headline image
Harmony Biosciences Holdings (NASDAQ:HRMY): A Prime Affordable Growth Stock with Strong Fundamentals ↗
Harmony Biosciences (HRMY) offers strong growth, solid valuation, and financial health, making it an ideal pick for Affordable Growth investors seeking high potential at reasonable prices. 
Via Chartmill
News headline image
Harmony Biosciences Holdings (NASDAQ:HRMY): A Strong Growth Stock with Promising Technical Setup ↗
Harmony Biosciences (HRMY) offers strong growth potential with solid fundamentals, high profitability, and a bullish technical setup, making it an attractive stock for investors. 
Via Chartmill
News headline image
Harmony Biosciences Reports Strong Q2 2025 Financial Results and Reaffirms 2025 Revenue Guidance; On Track to Announce Fragile X Topline Data From Phase 3 Registrational Trial in Q3 2025
From Harmony Biosciences Holdings, Inc.
Via Business Wire
News headline image
Harmony Biosciences Holdings (NASDAQ:HRMY) Presents a Compelling Value Investment Opportunity with Strong Fundamentals and Growth Potential ↗
Harmony Biosciences (HRMY) is undervalued with strong fundamentals—low P/E, high profitability, solid financials, and robust growth, making it a prime value investing opportunity. 
Via Chartmill
News headline image
Harmony Biosciences to Report Second Quarter 2025 Financial Results on August 5, 2025
From Harmony Biosciences Holdings, Inc.
Via Business Wire
News headline image
Harmony Biosciences Holdings (NASDAQ:HRMY) – A Strong Growth Stock with Attractive Valuation ↗
Harmony Biosciences (HRMY) offers strong growth, solid profitability, and an attractive valuation, making it a compelling choice for investors seeking affordable growth stocks in the pharmaceutical... 
Via Chartmill
News headline image
Harmony Biosciences to Participate in H.C. Wainwright "HCW@Home" Series
From Harmony Biosciences
Via Business Wire
News headline image
6 Analysts Assess Harmony Biosciences Hldgs: What You Need To Know ↗
 
Via Benzinga
< Previous 1 2 3 4 5 6 7 8 9 10 11 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.